Bayer is hoping to position asundexian as a successor to Johnson & Johnson-partnered anticoagulant Factor Xa inhibitor Xarelto (rivaroxaban ... but is nearing the loss of patent protection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback